Uroguanylin: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
== Uroguanylin == | |||
[[File:Uroguanylin.svg|thumb|right|Structure of Uroguanylin]] | |||
'''Uroguanylin''' is a [[peptide hormone]] that plays a significant role in the regulation of [[electrolyte]] and [[water balance]] in the body. It is primarily produced in the [[intestine]] and acts on the [[kidney]]s to promote the excretion of [[sodium]] and water, thus contributing to the maintenance of [[blood pressure]] and [[fluid homeostasis]]. | |||
== Structure and Function == | |||
Uroguanylin is a member of the [[guanylin]] family of peptides, which also includes [[guanylin]] and [[lymphoguanylin]]. These peptides activate the [[guanylate cyclase-C]] (GC-C) receptor, leading to an increase in intracellular [[cyclic GMP]] levels. This signaling pathway results in the secretion of [[chloride]] and [[bicarbonate]] ions into the intestinal lumen, followed by water, which aids in [[digestion]] and [[absorption]]. | |||
In the kidneys, uroguanylin acts to increase the excretion of sodium and water, a process known as [[natriuresis]]. This function is crucial for the regulation of [[extracellular fluid]] volume and [[blood pressure]]. | |||
== Synthesis and Secretion == | |||
Uroguanylin is synthesized as a [[prohormone]] in the [[enterocytes]] of the small intestine. It is then cleaved to its active form and secreted into the [[circulation]]. The secretion of uroguanylin is stimulated by the intake of [[dietary sodium]], which suggests its role in the body's response to [[salt]] intake. | |||
== Clinical Significance == | |||
Alterations in uroguanylin levels have been associated with various [[disease]] states. For instance, reduced levels of uroguanylin have been observed in patients with [[hypertension]] and [[chronic kidney disease]]. Understanding the role of uroguanylin in these conditions could lead to new therapeutic approaches. | |||
== Research and Development == | |||
Research into uroguanylin and its analogs is ongoing, with potential applications in the treatment of [[constipation]] and other gastrointestinal disorders. The development of drugs that mimic the action of uroguanylin could provide new options for patients with these conditions. | |||
== Related Pages == | |||
* [[Guanylin]] | |||
* [[Guanylate cyclase]] | |||
* [[Natriuresis]] | |||
* [[Peptide hormone]] | |||
{{Reflist}} | |||
[[Category:Peptide hormones]] | [[Category:Peptide hormones]] | ||
[[Category: | [[Category:Renal physiology]] | ||
[[Category:Digestive system]] | |||
Revision as of 12:02, 9 February 2025
Uroguanylin

Uroguanylin is a peptide hormone that plays a significant role in the regulation of electrolyte and water balance in the body. It is primarily produced in the intestine and acts on the kidneys to promote the excretion of sodium and water, thus contributing to the maintenance of blood pressure and fluid homeostasis.
Structure and Function
Uroguanylin is a member of the guanylin family of peptides, which also includes guanylin and lymphoguanylin. These peptides activate the guanylate cyclase-C (GC-C) receptor, leading to an increase in intracellular cyclic GMP levels. This signaling pathway results in the secretion of chloride and bicarbonate ions into the intestinal lumen, followed by water, which aids in digestion and absorption.
In the kidneys, uroguanylin acts to increase the excretion of sodium and water, a process known as natriuresis. This function is crucial for the regulation of extracellular fluid volume and blood pressure.
Synthesis and Secretion
Uroguanylin is synthesized as a prohormone in the enterocytes of the small intestine. It is then cleaved to its active form and secreted into the circulation. The secretion of uroguanylin is stimulated by the intake of dietary sodium, which suggests its role in the body's response to salt intake.
Clinical Significance
Alterations in uroguanylin levels have been associated with various disease states. For instance, reduced levels of uroguanylin have been observed in patients with hypertension and chronic kidney disease. Understanding the role of uroguanylin in these conditions could lead to new therapeutic approaches.
Research and Development
Research into uroguanylin and its analogs is ongoing, with potential applications in the treatment of constipation and other gastrointestinal disorders. The development of drugs that mimic the action of uroguanylin could provide new options for patients with these conditions.
Related Pages
<references group="" responsive="1"></references>